Obesity Management

The first iteration of Crisis Point addresses the obesity crisis in the United States and beyond, with expert interviews and discussion.

Episode 4 of Crisis Point asks the question you've been waiting for, "What is blueprint to resolving the obesity crisis?"

Data show 5 of 20 patients with history of MBS in the study experienced the primary composite outcome of IMV and/or death by day 7.

Episode 3 of Crisis Point examines the regional differences in obesity, from issues with nutrition and food insecurity to the use of the phrase "food desert".

Episode 2 of HCPLive Crisis Point tackles the clinical aspects and potential burdens clinicians face in the pursuit of obesity care.

Though previous studies have measured different levels of physical activity, few before this have considered the interrelationship involving body mass index and childhood asthma control.

HCPLive Crisis Point takes an in-depth look at the obesity crisis, beginning with the process of medical diagnosis and who is impacted the most by the disease.

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

Wellness trainers educate patients on how to begin exercise programs and then track progression and results of patients to aid in rehabilitation process.

There was little difference in hospitalization and mortality rates between vaccinated schizophrenia patients and vaccinated control patients.

Data show risk factors included education level and increased glucose level did not have signficant impact on BMI and body fat of children.

Data show both microvascular and macrovascular outcomes were significantly improved following bariatric intervention in patients with obesity.

Part 2 of a Q&A with Elena Christofides, MD highlighting important discussions surrounding ADA 2021, including semaglutide and obesity treatments as they relate to T2D.

New findings show patients were able to more than halve type 2 diabetes medication while improving diabetic and cardiovascular parameters in 8 weeks.

New SUPRASS-2 findings show the dual GIP/GLP-1 agonist provided superior type 2 diabetes management outcomes at 3 different doses.

A comparison of 3 standard dietary strategies for weight and glycemia control showed no difference in exercise metrics.

The indication makes the Novo Nordisk product the first weekly injection GLP-1 agonist approved for managing overweight and obesity.

A new study finds the top 10 future research priorities into diabetes and pregnancy.

A new CDC study shows the link between poor vision and heart disease is not just limited to cardiovascular events.

New data show a link between body mass index and increased risk of adverse effects from COVID-19.

Investigators collect study data from lengthy questionnaires relating to diet and demographics, finding that a high glycemic index correlates to more adverse effects in patients.

The PCSK9 inhibitor was linked to 27% mean reduction in LDL-C over 12 weeks.

Patients who continued taking semaglutide (Rybelsus/Novo Nordisk) after an initial 20-week therapy period saw continued weight loss, leading to the hope that a new pharmacologic approach to weight loss could be on the horizon.

Continuing treatment results in a nearly 8% reduction in weight during a 48 week period.

The approval represents the first ever therapy for chronic weight management for obesity caused by a trio of genetic deficiencies.

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

The daily oral capsule was shown to reduce overweight and obese patient weight by about 6% over 6 months.